Abby Reinhard

The registry aims to enroll approximately 800 patients with NMOSD to evaluate the efficacy of new medications and treatments.

Investigators note the potential effectiveness of integrating trunk-oriented exercises with existing conventional programs.

Investigators extended the follow-up period of the RESTART study, which concluded that antiplatelet therapy was safe for up to 5 years following intracerebral hemorrhage.

Investigators evaluated the effect of pain on sleep disturbance and vice-versa over time, finding stable differences between patients in sleep and pain.

Older adults with CI were found to require a significantly higher number of visits during home health care episodes, particularly skilled nursing visits.

Investigators concluded that the most sensitive screening tool for OSA in women with IIH was the STOP-BANG questionnaire.

Patients with chronic migraine were advised to reduce cannabis use to aid in reducing medication overuse headache.

Investigators found that strength training improved muscle strength, balance, gait speed, and gross motor function in pediatric and adolescent patients.

Investigators concluded that feedback from patients and caregivers should be incorporated as telehealth continues to be integrated into daily clinical care.

Internet-based cognitive behavioral therapy for insomnia program engagement was low and did not elicit a change in medication use or health care visits.

A recent study found that saffron had similar efficacy at both 14-mg and 28-mg doses, increasing melatonin levels but not cortisol.

Jennifer Hranilovich, MD, assistant professor of pediatrics and neurology at the University of Colorado School of Medicine, discussed a recent narrative review that evaluated research on headache in transgender and gender-diverse patients.

A literature review evaluated phase 3 trials in patients with secondary progressive multiple sclerosis, including trials dating back to 1990, to establish the most important measures used.

The neuro-ophthalmologist from UT Southwestern Medical Center provided her opinion on the state of care for patients with NMOSD and associated optic neuritis technology.

Investigators found incobotulinumtoxinA treatment decreased unstimulated salivary flow rate and increased GICS ratings in children.

Investigators found that frequency of MOG-Ab associated NMOSD was not significantly different between Asian and Caucasian populations despite the prevalence of NMOSD in Asian regions.

A recent systematic review investigated the use of virtual reality as a therapeutic tool compared to conventional interventions, finding its use may improve quality of life, fatigue, and balance.

Coauthor and member of the American Academy of Sleep Medicine board of directors, Lynn Marie Trotti, MD, MSc, discussed key takeaways from the new guideline, which encompasses the first updates since 2007.

Michael Weiner, MD, professor of radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California–San Francisco, discussed the findings of a systematic review aimed at evaluating models that predict dichotomous Aß.

The new guideline addresses recent FDA-approved prescription medications to treat narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome.

Yanhong Shi, PhD, director, stem cell biology research, City of Hope National Medical Center, discussed the potential of a new brain organoid model, which was developed to study sporadic Alzheimer disease.

Investigators used statistical analysis to evaluate the effectiveness of the treatment method, with results indicating it could be a viable method for patients with MS.

Investigators found that phase advance was associated with late-stage PD, mostly due to active offset advance, amplitude reduction, and weakened robustness.

Investigators found SESI-HRMS measurements could be useful for breath analysis in conjunction with OSA screening questionnaires.

The chief medical officer of NeuroPace discussed the newly developed nSight Platform, which allows physicians to remotely track seizure burden and activity for patients with drug-resistant focal epilepsy.

Investigators compared 4 treatment groups, concluding that nonstandard therapies were less effective in enacting freedom from treatment failure.

The chief medical officer of Wave Life Sciences, Michael Panzara, MD, MPH, discussed the potential of an investigational new treatment, WVE-004, for patients with C9orf72-associated ALS and FTD.

Surgery for eligible patients was shown to increase rates of seizure freedom, as well as improve developmental levels, among those with TSC.

Michael Panzara, MD, MPH, chief medical officer of Wave Life Sciences, spoke on the FOCUS-C9 study, which recently began dosing of an investigational treatment, WVE-004, for patients with ALS and FTD.

The autologous, expanded Treg cell therapy was found safe and tolerable in a phase 1 study of 3 patients with ALS.